Beam Therapeutics Inc

BEAM

26.520USD

+1.790+7.24%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Beam Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

70 / 392

Overall Ranking

190 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Beam Therapeutics Inc Highlights

StrengthsRisks

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Growing

The company is in a growing phase, with the latest annual income totaling USD 63.52M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 63.52M.

Fairly Valued

The company’s latest PE is -6.01, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 103.60M shares, increasing 0.02% quarter-over-quarter.

Held by HACAX

Star Investor HACAX holds 3.42K shares of this stock.

Analyst Rating

Based on 18 analysts

Buy

Current Rating

46.520

Target Price

+88.11%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Beam Therapeutics Inc is 5.99, ranking 304 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 9.70M, representing a year-over-year decrease of 32.03%, while its net profit experienced a year-over-year decrease of 16.61%.

Score

Industry at a Glance

Previous score

5.99

Change

0



Financials

6.78

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.98

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Beam Therapeutics Inc is 6.32, ranking 297 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.01, which is -47.52% below the recent high of -3.15 and -336.72% above the recent low of -26.24.

Score

Industry at a Glance

Previous score

6.32

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 70/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Beam Therapeutics Inc is 8.78, ranking 58 out of 392 in the Biotechnology & Medical Research industry. The average price target is 42.00, with a high of 80.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

8.78

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Beam Therapeutics Inc is 6.84, ranking 155 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 33.87 and the support level at 21.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.57

Change

0.27

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Beam Therapeutics Inc is 10.00, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 114.47%, representing a quarter-over-quarter decrease of 1.20%. The largest institutional shareholder is Catherine Wood, holding a total of 12.47M shares, representing 12.29% of shares outstanding, with 45.69% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

ARK Investment Management LLC

Star Investors

11.04M

+6.04%

Fidelity Management & Research Company LLC

11.27M

-10.04%

Farallon Capital Management, L.L.C.

10.06M

+0.50%

The Vanguard Group, Inc.

Star Investors

9.23M

-4.74%

BlackRock Institutional Trust Company, N.A.

6.78M

+0.81%

ARCH Venture Partners

4.54M

--

Amova Asset Management Co., Ltd.

4.83M

+2.14%

State Street Investment Management (US)

4.01M

+10.18%

Bellevue Asset Management AG

2.89M

--

Kynam Capital Management LP

2.52M

+4.14%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Beam Therapeutics Inc is 4.52, ranking 83 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 2.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Beam Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Beam Therapeutics Inc

BEAM

7.02 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment